Dashboard
1
Poor Management Efficiency with a low ROCE of 6.47%
- The company has been able to generate a Return on Capital Employed (avg) of 6.47% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Flat results in Mar 25
4
With ROE of 6.04%, it has a fair valuation with a 0.93 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
VND 250,427 Million (Micro Cap)
15.00
NA
0.65%
1.73
6.03%
0.91
Revenue and Profits:
Net Sales:
161,231 Million
(Quarterly Results - Mar 2025)
Net Profit:
2,044 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.37%
0%
0.37%
6 Months
2.92%
0%
2.92%
1 Year
0.37%
0%
0.37%
2 Years
15.37%
0%
15.37%
3 Years
36.58%
0%
36.58%
4 Years
-6.57%
0%
-6.57%
5 Years
10.28%
0%
10.28%
Ben Tre Pharmaceutical JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.24%
EBIT Growth (5y)
11.61%
EBIT to Interest (avg)
1.17
Debt to EBITDA (avg)
6.97
Net Debt to Equity (avg)
1.86
Sales to Capital Employed (avg)
1.13
Tax Ratio
40.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.47%
ROE (avg)
9.10%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.93
EV to EBIT
12.79
EV to EBITDA
9.89
EV to Capital Employed
0.98
EV to Sales
0.89
PEG Ratio
NA
Dividend Yield
0.64%
ROCE (Latest)
7.63%
ROE (Latest)
6.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
161,230.70
185,370.30
-13.02%
Operating Profit (PBDIT) excl Other Income
17,376.50
16,829.50
3.25%
Interest
10,257.00
9,927.60
3.32%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,043.70
6,107.20
-66.54%
Operating Profit Margin (Excl OI)
79.10%
63.00%
1.61%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is -13.02% vs 6.75% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is -66.54% vs -39.32% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
868,411.30
811,616.20
7.00%
Operating Profit (PBDIT) excl Other Income
66,220.50
75,978.50
-12.84%
Interest
40,192.90
49,685.30
-19.11%
Exceptional Items
3,374.10
0.00
Consolidate Net Profit
11,157.70
17,466.20
-36.12%
Operating Profit Margin (Excl OI)
56.60%
82.70%
-2.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 7.00% vs 7.55% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -36.12% vs -56.87% in Dec 2023
About Ben Tre Pharmaceutical JSC 
Ben Tre Pharmaceutical JSC
Pharmaceuticals & Biotechnology
Ben Tre Pharmaceutical JSC (Bepharco) is a Vietnam-based company engaged in the pharmaceutical industry. The Company is involved in the wholesaling, import and export of pharmaceutical products, materials, chemicals, packagings and biological products. It is also engaged in the manufacturing of pharmaceutical and medicinal products through its subsidiaries, as well as the retailing of drugs. In addition, the Company trades supplements, medical equipment, supplies and machinery. The Company also rents out space for commercial purposes.
Company Coordinates 
Company Details
So 6A3, Quoc lo 60, Phuong Phu Tan , BEN TRE None : None
Registrar Details






